This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Edgar, T. S. Search for Related Content PubMed PubMed Citation Articles by Edgar, T. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Botox Cerebral Palsy Social Bookmarking                         What's this?

Clinical Utility of Botulinum Toxin in the Treatment of Cerebral Palsy: Comprehensive Review

Arkansas Children's Hospital, 800 Marshall Street, Little Rock, AR 72202

The physical properties, mechanism of action, and clinical evidence supporting the use of botulinum toxin in the management of spasticity in cerebral palsy are discussed. Assessment methods, patient selection criteria, and methodology for preparation and administration of botulinum toxin are discussed in detail and a treatment algorithm based on the cumulative experience of the author is provided. Botulinum toxin type A is well tolerated, safe, and effective in the treatment of patients with spastic cerebral palsy. Appropriate patient selection is imperative. Treatment goals need to be well defined and tailored to the individual patient's needs. Growth and development is a continuous and evolving process, necessitating the constant reassessment of the patient and modification of future treatment goals. The ultimate success of management in cerebral palsy is dependent on the development of a comprehensive spasticity team with complementing skills who, together, can significantly improve the quality of life of these patients. (J Child Neurol 2001;16:37-46).

Journal of Child Neurology, Vol. 16, No. 1, 37-46 (2001)
DOI: 10.1177/088307380101600107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. I. Dai, M. Wasay, and S. Awan Botulinum Toxin Type A with Oral Baclofen Versus Oral Tizanidine: A Nonrandomized Pilot Comparison in Patients with Cerebral Palsy and Spastic Equinus Foot Deformity J Child Neurol, December 1, 2008; 23(12): 1464 - 1466. [Abstract] [PDF]

				K. W Nolan, L. L Cole, and G. S Liptak Use of Botulinum Toxin Type A in Children With Cerebral Palsy Physical Therapy, April 1, 2006; 86(4): 573 - 584. [Full Text] [PDF]

				D. Steenbeek, A. Meester-Delver, J. G Becher, and G. J Lankhorst The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling Clinical Rehabilitation, March 1, 2005; 19(3): 274 - 282. [Abstract] [PDF]

				P. Rosenbaum Cerebral palsy: what parents and doctors want to know BMJ, May 3, 2003; 326(7396): 970 - 974. [Full Text] [PDF]

				P. Rosenbaum Controversial Treatment of Spasticity: Exploring Alternative Therapies for Motor Function in Children With Cerebral Palsy J Child Neurol, January 1, 2003; 18(1_suppl): S89 - S94. [Abstract] [PDF]

				A. Fattal-Valevski, N. Giladi, D. Domanievitz, L. Zuk, R. Masterman, S. Harel, S. Wientroub, and S. Hayek Parameters for Predicting Favorable Responses to Botulinum Toxin in Children With Cerebral Palsy J Child Neurol, April 1, 2002; 17(4): 272 - 276. [Abstract] [PDF]